Literature DB >> 24961751

Early corticosteroids requirement after the diagnosis of ulcerative colitis diagnosis can predict a more severe long-term course of the disease - a nationwide study of 1035 patients.

N H Khan1, R M Almukhtar, E B Cole, A M Abbas.   

Abstract

BACKGROUND: There are limited data regarding clinical outcomes in ulcerative colitis (UC) patients who require early corticosteroids (CS) use. AIM: To evaluate the rate of early CS utilisation (within 30 days of diagnosis) as a predictive marker for long-term outcomes, colectomy and CS dependency, in a population-based cohort of incident UC cases.
METHODS: Nationwide data were obtained from the Veterans Affairs (VA) health care system for the period 2001-2011. Incident UC cases were identified. A retrospective cohort design and time-to-event survival analysis were used to track outcomes of interest. Cox regression multivariate analysis was employed.
RESULTS: One thousand and thirty-five newly diagnosed patients with UC were identified and included in the analysis; 236 (23%) of those patients required early CS therapy. Patients were followed-up over a median time of 4.7 years (IQR 2.8-6.8) after UC diagnosis. The 5-year cumulative probability of requiring colectomy varied significantly by early CS use status (13% among early CS users compared to 4% among those who did not require early CS treatment, P < 0.001). Similar variation in the 5-year cumulative probability of CS dependency by early CS status was observed. Early CS users were more likely to require colectomy 2.9 (CI 1.7-5.0, P < 0.001) and to become CS dependent 4.5 (95% CI 3.6-5.7, P < 0.001) than non-users.
CONCLUSIONS: Early CS use can help identify those patients who have a more active disease course of UC. Recognising this can be among the indicators that can help physicians identify patients who may require early initiation of more aggressive therapy.
© 2014 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24961751     DOI: 10.1111/apt.12834

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  14 in total

Review 1.  AGA Technical Review on the Management of Mild-to-Moderate Ulcerative Colitis.

Authors:  Siddharth Singh; Joseph D Feuerstein; David G Binion; William J Tremaine
Journal:  Gastroenterology       Date:  2018-12-18       Impact factor: 22.682

2.  Short-Term Clinical Response to Corticosteroids Can Predict Long-Term Natural History of Ulcerative Colitis: Prospective Study Experience.

Authors:  Tarun Rai; Bikash Narayan Choudhury; Saurabh Kedia; Sawan Bopanna; Pratap Mouli Venigalla; Sushil Kumar Garg; Vikas Singla; Govind Makharia; Vineet Ahuja
Journal:  Dig Dis Sci       Date:  2017-02-04       Impact factor: 3.199

Review 3.  Current overview of opioids in progression of inflammatory bowel disease; pharmacological and clinical considerations.

Authors:  Naser-Aldin Lashgari; Nazanin Momeni Roudsari; Nadia Zandi; Benyamin Pazoki; Atiyeh Rezaei; Mehrnoosh Hashemi; Saeideh Momtaz; Roja Rahimi; Maryam Shayan; Ahmad Reza Dehpour; Amir Hossein Abdolghaffari
Journal:  Mol Biol Rep       Date:  2021-01-04       Impact factor: 2.316

4.  A Novel Model for Predicting Incident Moderate to Severe Anemia and Iron Deficiency in Patients with Newly Diagnosed Ulcerative Colitis.

Authors:  Nabeel Khan; Dhruvan Patel; Yash Shah; Yu-Xiao Yang
Journal:  Dig Dis Sci       Date:  2017-03-11       Impact factor: 3.199

5.  Elderly-Onset and Adult-Onset Ulcerative Colitis Are More Similar than Previously Reported in a Nationwide Cohort.

Authors:  Vinayak Kumar; Yash Shah; Dhruvan Patel; Nabeel Khan
Journal:  Dig Dis Sci       Date:  2017-09-07       Impact factor: 3.199

6.  Early Response to Corticosteroid and Baseline C-Reactive Protein Predicts Outcomes in Children with Moderate to Severe Ulcerative Colitis.

Authors:  Gayetri Deva Rajoo; Lian Tan; Ainslie Lopez; Peter Lewindon; Zubin Grover
Journal:  Dig Dis Sci       Date:  2019-02-07       Impact factor: 3.487

7.  Albumin as a prognostic marker for ulcerative colitis.

Authors:  Nabeel Khan; Dhruvan Patel; Yash Shah; Chinmay Trivedi; Yu-Xiao Yang
Journal:  World J Gastroenterol       Date:  2017-12-07       Impact factor: 5.742

8.  Low dose Naltrexone for induction of remission in inflammatory bowel disease patients.

Authors:  Mitchell R K L Lie; Janine van der Giessen; Gwenny M Fuhler; Alison de Lima; Maikel P Peppelenbosch; Cokkie van der Ent; C Janneke van der Woude
Journal:  J Transl Med       Date:  2018-03-09       Impact factor: 5.531

9.  Relationship between mucosal healing by tacrolimus and relapse of refractory ulcerative colitis: a retrospective study.

Authors:  Ayumi Ito; Syun Murasugi; Teppei Omori; Shinichi Nakamura; Katsutoshi Tokushige
Journal:  BMC Gastroenterol       Date:  2020-06-26       Impact factor: 3.067

Review 10.  Optimal management of steroid-dependent ulcerative colitis.

Authors:  Hafiz M Waqas Khan; Faisal Mehmood; Nabeel Khan
Journal:  Clin Exp Gastroenterol       Date:  2015-11-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.